Slides to accompany the "Industry perspective" panel presentation by Allan Bowyer, Janssen Pharmaceuticals, @abowy.
Janssen aims to address the full continuum of cancer care and the next frontier – the era of personalised medicines. How is mHealth helping them to achieve these aims?
----
This was presented at the "Unleashing the mHealth potential for cancer patients" event held on Wednesday 25th May 2016 (16:30-18:30pm) in the European Parliament.
#mHealthCancer
"mHealth and eHealth are becoming realities in Europe: this is demonstrated by the growing size of mHealth apps’ market, by the raising investments in eHealth infrastructures and by the fast adoption, at various degrees, of mHealth applications by patients.
The burden of cancer is also raising: more than 10 million EU citizens are affected by cancer, incidence and prevalence are growing, and the socio-economic impact of cancer heavily burdens both healthcare systems and cancer patients.
The recent political agreement on the text the General Data Protection Regulation and the production of the Privacy Code of Conduct mHealth apps further stir the debate regarding the use of new mHealth technologies within cancer care pathways.
Are cancer patients enjoying the benefits of mHealth?
In which field can cancer patients profit the most from mHealth apps?
Is the regulatory framework supporting the development of useful and safe mHealth apps for cancer patients?
Are there other structural obstacles to the full integration of mHealth apps in the cancer patients’ journey?"
The event will be hosted by MEP Cristian-Silviu Busoi (EPP, Romania), one of ECPC closest champions within the European Parliament and a knowledgeable supporter of the development of eHealth/mHealth in Europe.
The event was followed by a cocktail reception.
Join the discussion on Twitter using #mHealthCancer The event is part of the initiatives for the
2016 European Week Against Cancer #EWAC2016
More information can be found on the European Cancer Patient Coalition's website:
http://www.ecpc.org/pressroom/events/icalrepeat.detail/2016/04/26/61/-/-
6. Good adherence is the sine qua non for
personalized medicines
“Increasing the effectiveness of adherence
interventions may have a far greater impact on
the health of the population than any
improvement in specific medical treatments3”
13. From the Dashboard, providers can:
• Monitor patients’ adherence by medication
• Print patient opt-in instructions
• Sort data by Name, Adherence Percentage & Alert
• Create and print Individual Medication Plans
• Print individual adherence reports
14. Parting thoughts
• The most expensive treatment is that which goes unused
• Deliver personalized adherence support with a human touch
• Put people before process and technology
15. References
1. Adherence to Long-TermTherapies, Evidence for Action,World Health
Organization, 2003
2. http://www.efpia.eu/topics/people-health/patient-adherence (retrieved 12
Feb 2016)
3. Attributed to Haynes et al in Adherence to long-TermTherapies, Evidence for
Action,World Health Organization, 2003
4. http://jrs.sagepub.com/content/104/12/510.full (retrieved 12 Feb 2016)
5. Adapted from McLeroy et al. Health Educ Q 1988;15(4):351-77; Berben et al.
WJNR, 2012 [adapted from Bronfenbrenner (1977, 1980)
